XML 34 R9.htm IDEA: XBRL DOCUMENT v3.20.1
RESTRUCTURING PLAN
 3 Months Ended
Mar. 31, 2020
Restructuring and Related Activities [Abstract]  
RESTRUCTURING PLAN
RESTRUCTURING PLAN

In August 2019, the Company began implementing two phases of a cost restructuring plan to streamline the organization, reduce costs, and direct resources to advance cobomarsen and miR-29 mimics, including remlarsen and MRG-229, while reducing investments in new discovery research. The restructuring plan identified approximately 44 positions for elimination, or approximately 50% of the Company’s then total workforce. The eliminated positions were primarily related to research and development and corresponding project, general, and administrative support. Through March 31, 2020, the Company had recorded cumulative restructuring expense of $2.2 million and expects to incur approximately $0.2 million in additional restructuring expense, primarily related to retention, during the remainder of 2020.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Company recorded $0.1 million in restructuring charges during the three months ended March 31, 2020, which was primarily related to retention transactions and recorded in research and development expenses on the condensed consolidated statements of operations and comprehensive loss.

The following table summarizes the Company’s accrued restructuring liability balance and associated activity (in thousands):
 
 
December 31, 2019
 
Additions
 
Cash Payments
 
March 31, 2020
Retention
 
$
935

 
$
119

 
$
(935
)
 
$
119

Severance and severance-related expenses
 
580

 
—

 
(283
)
 
297

Total restructuring liability
 
$
1,515

 
$
119

 
$
(1,218
)
 
$
416